The National Cancer Institute’s Investigational New Drug program facilitates collaboration, not collusion, with industry for ...

In a landmark decision poised to revolutionize drug development, the U.S. Food and Drug Administration (FDA) has announced a ...

The initiative, which will start with monoclonal antibodies, is the first big regulatory shift from the FDA since Martin ...

The FDA will begin replacing animal testing in the development of monoclonal antibody therapies and other drugs with ...

The FDA laid out a three-year roadmap to phase out animal toxicity testing in drug research. In addition to organoids and lab ...

The FDA granted a positive review for an acute myeloid leukemia drug trial, with initial dosing expected in 2025.

Moving the drug toward human trials faces significant hurdles, primarily funding. Wang estimated the next phase will cost ...

today announced that the U.S. Food and Drug Administration (FDA) has cleared Altesa's new Investigational New Drug (IND) application for vapendavir for the treatment of rhinovirus infections in ...

BIIB080 marks the first antisense oligonucleotide targeting tau to enter clinical development for the treatment of Alzheimer ...

The company plans to submit an Investigational New Drug (IND) application to the U.S. Food and Drug Administration for ATL-201 in 2025. “We believe these preclinical results underscore the ...